You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1257 Augmenting post-market surveillance of serious drug-induced adverse events with artificial intelligence (AI)-aggregated case reports: proof-of-concept for PD-1/PD-L1 inhibitors for NSCLC

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immunotherapy Toxicities
1257 Augmenting post-market surveillance of serious drug-induced adverse events with artificial intelligence (AI)-aggregated case reports: proof-of-concept for PD-1/PD-L1 inhibitors for NSCLC
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address